Lycobetaine, also known as Ungeremine, is primarily studied for its potential in cancer treatment. It exhibits antitumor properties by interfering with the growth and proliferation of cancer cells. Researchers are exploring its use in chemotherapy, particularly for its ability to target specific cellular mechanisms that are crucial for tumor survival. Additionally, Lycobetaine is being investigated for its role in inducing apoptosis, or programmed cell death, in cancer cells, which makes it a promising candidate for developing new anticancer drugs. Its application is still largely in the experimental and research phases, with ongoing studies to better understand its efficacy and safety in clinical settings.